Anteris Posts 30c Q2 Loss as Trial Costs Widen
AVR has more than doubled off its 52-week low of $3.175.
Summary
Anteris reported a Q2 loss of 30 cents per share, widening from prior periods as spending on the PARADIGM trial escalates. The company holds $260.9M in cash, providing runway, but the loss underscores the burn rate ahead of key clinical milestones. This follows a series of insider sales by major holder L1 Capital, which offloaded over $13M in shares across late July and early August. The 10-Q also flags persistent material weaknesses in internal controls. With the French regulatory clearance secured in June, the trial's progress and cash consumption will be the critical metrics to track. Second quarter sales were $1.01M.
At the time of this announcement, AVR was trading at $9.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $892.6M. The 52-week trading range was $3.18 to $11.06. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.